hepatitis c

View All

pharma-news-for-biogen-eisai-quidel-accutar-boehringer
Biogen-Eisai’s Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab

Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s app...

Find More

Hepatitis B and C Treatment and Upcoming Therapies
Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Hepatitis is an infection that causes inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis viruses are the most common cause of hepatitis; however, other infections such as toxic substances (e.g., alcohol, certain drugs) and auto...

Find More

Recent-pharma-news
Algernon’s NP-120; FDA nod to 4DMedical tool; SaNOtize’s NORSTM trial; Pole’s capital increase

Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.  The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...

Find More

Cardiovascular Disease
Cardiovascular Disease: A major cause of health loss and a global burden

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National Vital Statistics Report, every 37 seconds, one person dies of Cardiovascular diseases in the US.  Cardiovascular diseases also known as heart disease, encompasses a wide range...

Find More

Hot flashes
Notizia

TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains molecularly identical (bio-identical) versions of the hormones estradiol and progesterone for menopausal women with a...

Find More

Gilead Sciences  launched a highly effective hepatitis C drug Sovaldi

Gilead Sciences has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment course at the same time when ‘How to price a cure’ discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it's very cost-ef...

Find More

Hepatitis C drugs re-energize global fight over patents

The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in thos...

Find More